SCHEMBL5865196

SCHEMBL5865196

[O-][n+]1ccccc1C=Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.51
FBP1 P09467 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
PTGES2 Q9H7Z7 4/20 0.46
MAOB P27338 3/20 0.42
P4HB P07237 1/20 0.41
LMNA P02545 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MAPT P10636 1/20 0.41
PKM P14618 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAOA P21397 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PCTP Q9UKL6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865193 1.00 NFE2L2 (0.51) NFE2L2FBP1MEN1KMT2ANPC1
SCHEMBL5864970 0.80 NFE2L2 (0.58) NFE2L2FBP1MEN1KMT2ANPC1
SCHEMBL5864976 0.80 NFE2L2 (0.58) NFE2L2FBP1MEN1KMT2ANPC1
SCHEMBL4712805 0.77 RAB9A (0.67) NFE2L2MEN1KMT2ANPC1RAB9A
SCHEMBL5496405 0.77 NFE2L2 (0.73) NFE2L2FBP1MEN1KMT2ANPC1
SCHEMBL4712807 0.77 RAB9A (0.67) NFE2L2MEN1KMT2ANPC1RAB9A
SCHEMBL3904046 0.77 NFE2L2 (0.73) NFE2L2FBP1MEN1KMT2ANPC1
SCHEMBL5865241 0.77 CHAT (0.57) FBP1MEN1KMT2ANPC1RAB9A
SCHEMBL5865244 0.77 CHAT (0.57) FBP1MEN1KMT2ANPC1RAB9A
SCHEMBL13790316 0.75 NFE2L2 (0.82) NFE2L2FBP1MEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1837195-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2006-09-27 CN disclosed
US-7034044-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2006-04-25 US disclosed
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER 2006-03-16 US disclosed
US-6951875-B2 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. (US) 2005-10-04 US disclosed
CN-1578662-A Pyridine derivatives as nmda-receptor subtype blockers HOFFMANN LA ROCHE (CH) 2005-02-09 CN disclosed
EP-1443926-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-11 EP disclosed
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent ALANINE ALEXANDER (FR) 2004-04-08 US disclosed
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent HOFFMANN-LA ROCHE INC. 2003-07-31 US disclosed
WO-2003037333-A1 PYRIDINE DERIVATIVES AS NMDA-RECEPTOR SUBTYPE BLOCKERS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040068118-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C NFE2L2 1274/4885FBP1 3031/4885MEN1 2517/4885
US-20030144525-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN1, GRIN2C NFE2L2 1274/4885FBP1 3031/4885MEN1 2517/4885
US-20060058354-A1 Conjugated aromatic compounds with a pyridine substituent GRIN2B, GRIN3A, GRIN2C NFE2L2 1407/4885FBP1 3436/4885MEN1 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.